Sunday, March 24, 2019

Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab.


from Reuters: Health News https://ift.tt/2uiKll4

Related Posts:

  • LATEST HEALTH NEWS(Reuters Health) - Younger boys who play lacrosse are more likely to get injured and sustain concussions than high school or college players, a U.S. study suggests. from Reuters: Health News https://reut.rs/2VzY7jq … Read More
  • LATEST HEALTH NEWSEli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that i… Read More
  • LATEST HEALTH NEWSChina has pledged to stem a flood of the synthetic opioid fentanyl onto America's streets, where it kills thousands of people a month, but U.S. security experts are skeptical about whether Beijing is willing, or even able, to… Read More
  • LATEST HEALTH NEWS(Reuters Health) - States that require adults on Medicaid to work a set number of hours to get benefits may find many people lose coverage because behavioral health conditions and other chronic health problems make it hard fo… Read More
  • LATEST HEALTH NEWS(Reuters Health) - Patients who see their doctors in the morning are a lot more likely to be referred for screenings for breast and colon cancer than patients with end-of-the-day appointments, a new study suggests. from … Read More

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner